Belgian biotechnology company Bone Therapeutics has appointed Jean Stéphenne as its new chairman of the board of directors, succeeding Steve Swinson in the process.
Stéphenne’s career history has seen him serve in senior leadership roles at several biotechnology and pharmaceutical companies, most recently as chairman of TiGenix.
He has also been a member of the corporate executive team for GlaxoSmithKline and chief executive officer of GSK Biologicals (now GSK Vaccines).
Thomas Lienard, chief executive officer of Bone Therapeutics, said: “Stéphenne has unparalleled experience in drug development and building innovative life science companies and is highly regarded within the sector.
“He will be a valuable addition to an already strong board as we advance our allogeneic cell therapy platform through clinical studies.”